blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2563811

EP2563811 - Immunoassay for Chromogranin A, antibodies and kit [Right-click to bookmark this link]
Former [2013/10]IMMUNOASSAY FOR CHROMOGRANIN A, ANTIBODIES AND KIT
[2016/38]
StatusNo opposition filed within time limit
Status updated on  12.01.2018
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  03.02.2017
FormerGrant of patent is intended
Status updated on  25.01.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Euro-Diagnostica AB
P.O. Box 50117
202 11 Malmö / SE
[2017/10]
Former [2013/10]For all designated states
Euro-diagnostica AB
P.O. Box 50117
202 11 Malmö / SE
Inventor(s)01 / STRIDSBERG, Mats
Grandungevagen 13
756 46 Uppsala / SE
02 / SOMMARIN, Yngve
P.O. Box 50117
202 11 Malmö / SE
 [2013/10]
Representative(s)Zacco Denmark A/S
Arne Jacobsens Allé 15
2300 Copenhagen S / DK
[N/P]
Former [2017/10]Habets, Winand
Life Science Patents
PO Box 5096
6130 PB Sittard / NL
Former [2013/10]Habets, Winand
Life Science Patents P.O. Box 5096
6130 PB Sittard / NL
Application number, filing date11716561.328.04.2011
[2017/10]
WO2011EP56763
Priority number, dateEP2010016137528.04.2010         Original published format: EP 10161375
[2013/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011135035
Date:03.11.2011
Language:EN
[2011/44]
Type: A1 Application with search report 
No.:EP2563811
Date:06.03.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2011 takes the place of the publication of the European patent application.
[2013/10]
Type: B1 Patent specification 
No.:EP2563811
Date:08.03.2017
Language:EN
[2017/10]
Search report(s)International search report - published on:EP03.11.2011
ClassificationIPC:C07K16/18, G01N33/53, G01N33/577, G01N33/68
[2013/10]
CPC:
G01N33/577 (EP,US); G01N33/68 (US); C07K16/18 (EP,US);
C07K16/26 (US); C07K16/30 (US); G01N33/53 (US);
G01N33/74 (EP,US); C07K2317/34 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/10]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:Immunoassay für Chromogranin A, sowie Antikörper und Kit[2016/38]
English:Immunoassay for Chromogranin A, antibodies and kit[2016/38]
French:Dosage immunologique de la Chromogranine A, anticorps et kit[2016/38]
Former [2013/10]IMMUNASSAY FÜR CHROMOGRANIN A, ANTIKÖRPER UND KIT
Former [2013/10]IMMUNOASSAY FOR CHROMOGRANIN A, ANTIBODIES AND KIT
Former [2013/10]DOSAGE IMMUNOLOGIQUE DE LA CHROMOGRANINE A, ANTICORPS ET KIT
Entry into regional phase23.10.2012National basic fee paid 
23.10.2012Designation fee(s) paid 
23.10.2012Examination fee paid 
Examination procedure23.10.2012Examination requested  [2013/10]
04.07.2013Amendment by applicant (claims and/or description)
25.06.2014Despatch of a communication from the examining division (Time limit: M04)
24.10.2014Reply to a communication from the examining division
01.12.2015Despatch of a communication from the examining division (Time limit: M02)
01.02.2016Reply to a communication from the examining division
27.09.2016Communication of intention to grant the patent
20.01.2017Fee for grant paid
20.01.2017Fee for publishing/printing paid
20.01.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.06.2014
Opposition(s)11.12.2017No opposition filed within time limit [2018/07]
Fees paidRenewal fee
29.04.2013Renewal fee patent year 03
28.04.2014Renewal fee patent year 04
27.04.2015Renewal fee patent year 05
27.04.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.04.2011
AL08.03.2017
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
TR08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
[2020/33]
Former [2020/15]HU28.04.2011
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
TR08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2019/51]HU28.04.2011
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2019/46]HU28.04.2011
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2019/31]HU28.04.2011
AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/43]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
IE28.04.2017
LU28.04.2017
MT28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/23]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
IE28.04.2017
LU28.04.2017
BE30.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/14]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
LU28.04.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/09]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/06]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2017/51]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2017/50]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SK08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
Former [2017/49]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RO08.03.2017
RS08.03.2017
SK08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
Former [2017/48]CZ08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RS08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
Former [2017/41]FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RS08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
Cited inInternational search[AD]EP1078266  (CIS BIO INT [FR]) [AD] 1-4 * examples 2, 3; claims 1-21; tables 2, 3 * * the whole document *;
 [IA]  - TARTAGLIA ANDREAS ET AL, "Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.", VIRCHOWS ARCHIV : AN INTERNATIONAL JOURNAL OF PATHOLOGY APR 2006 LNKD- PUBMED:16408221, (200604), vol. 448, no. 4, ISSN 0945-6317, pages 399 - 406, XP002585661 [I] 1-3 * tables 2, 3 * * the whole document * [A] 4

DOI:   http://dx.doi.org/10.1007/s00428-005-0113-1
 [IA]  - PORTELA-GOMES G M ET AL, "Chromogranin A in human neuroendocrine tumors: An immunohistochemical study with region-specific antibodies", AMERICAN JOURNAL OF SURGICAL PATHOLOGY, RAVEN PRESS, NEW YORK, NY, US, (20010101), vol. 25, no. 10, ISSN 0147-5185, pages 1261 - 1267, XP009134371 [I] 1-3 * tables 2, 3 * * the whole document * [A] 4
 [A]  - CORTI A ET AL, "Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains.", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS 15 JAN 1996 LNKD- PUBMED:8631342, (19960115), vol. 235, no. 1-2, ISSN 0014-2956, pages 275 - 280, XP002585662 [A] 1-4 * abstract *
 [A]  - GILL B M ET AL, "Chromogranin a epitopes: Clues from synthetic peptides and peptide mapping", NEUROPEPTIDES, CHURCHILL LIVINGSTONE, GB LNKD- DOI:10.1016/0143-4179(92)90521-W, vol. 21, no. 2, ISSN 0143-4179, (19920201), pages 105 - 118, (19920201), XP026324392 [A] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1016/0143-4179(92)90521-W
 [A]  - STRIDSBERG M, "Measurements of chromogranins and chromogranin-related peptides by immunological methods.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2000 LNKD- PUBMED:11192592, (2000), vol. 482, ISSN 0065-2598, pages 319 - 327, XP009134372 [A] 1-4 * the whole document *
Examination   - PORTELA-GOMES GUIDA MARIA ET AL, "Selective processing of chromogranin A in the different islet cells in human pancreas", JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, (200104), vol. 49, no. 4, doi:doi:10.1177/002215540104900408, ISSN 0022-1554, pages 483 - 490, XP055140080

DOI:   http://dx.doi.org/10.1177/002215540104900408
by applicantUS4758522
 EP1078266
    - BAJETTA, E., FERRARI, L., MARTINETTI, A., CELIO, L., PROCOPIO, G., ARTALE, S., ZILEMBO, N., DI BARTOLOMEO, M., SEREGNI, E., BOMBAR, "Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patient with neuroendocrine tumours", CANCER, (1999), vol. 86, pages 858 - 865
    - ERIKSSON, B., OBERG, K., STRIDSBERG, M., "Tumour markers in neuroendocrine tumours", DIGESTION, (2000), vol. 62, pages 33 - 38
    - K6HLER, MILSTEIN, NATURE, (1975), vol. 256, page 495
    - KONECKI ET AL., BIOL. CHEM., (1987), vol. 262, pages 17026 - 17030
    - O'CONNOR, D.T., DEFTOS, L.J., "Secretion of chromogranin A by peptide-producing endocrine neoplasms", NEW ENGLAND JOURNAL OF MEDICINE, (1986), vol. 314, pages 1145 - 1151
    - STRIDSBERG, M., HELLMAN, U., WILANDER, E., LUNDQVIST, G., HELLSING, K., OBERG, K., "Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments", JOURNAL OF ENDOCRINOLOGY, (1993), vol. 139, pages 329 - 337
    - STRIDSBERG, M., OBERG, K., LI, Q., ENGSTR6M, U., LUNDQVIST, G., "Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours", JOURNAL OF ENDOCRINOLOGY, (1995), vol. 144, pages 49 - 59, XP009130179
    - STRIDSBERG, M., "Measurements of chromogranins and chromogranin-related peptides by immunological methods", ADVANCED EXPERIMENTAL AND MEDICAL BIOLOGY, (2000), vol. 482, pages 319 - 327, XP009134372
    - WINKLER, H., FISCHER-COLBRIE, R., "The chromogranin A and B: The first 25 years and future perspectives", NEUROSCIENCE, (1992), vol. 49, doi:doi:10.1016/0306-4522(92)90222-N, pages 497 - 528, XP024385810

DOI:   http://dx.doi.org/10.1016/0306-4522(92)90222-N
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.